Home / Recalls / Amneal Pharmaceuticals of New York, LLC / D-1349-2020

D-1349-2020 Class II Ongoing

Recalled by Amneal Pharmaceuticals of New York, LLC — Brookhaven, NY

Recall Details

Product Type
Drugs
Report Date
July 1, 2020
Initiation Date
May 29, 2020
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

amneal Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, Rx only, 100 Tablets bottles, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad, 388213, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 NDC 65162-179-10

Reason for Recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Distribution Pattern

Nationwide

Code Information

AM181337A 10/31/2020 AM181338A 10/31/2020 AM181339A 11/30/2020 AM181340A 11/30/2020 AM181341A 11/30/2020 AM181342A 11/30/2020 AM181343A 11/30/2020 AM181344A 11/30/2020 AM181356A 11/30/2020 AM181357A 11/30/2020 AM181358A 11/30/2020 AM181359A 11/30/2020 AM181360A 11/30/2020 AM181361A 11/30/2020 AM181362A 11/30/2020 AM181363A 11/30/2020 AM181415A 11/30/2020 AM190040B 12/31/2020 AM190041A 12/31/2020 AM190042A 12/31/2020 AM190043A 12/31/2020 AM190044A 12/31/2020 AM190045A 12/31/2020 AM190046A 12/31/2020 AM190473B 4/30/2021 AM190474A 4/30/2021 AM190475A 4/30/2021 AM190476A 4/30/2021 AM190477A 4/30/2021 AM190478A 4/30/2021 AM190479A 4/30/2021 AM190480A 4/30/2021 AM190481A 4/30/2021 AM190482A 4/30/2021 AM190834A 7/31/2021 AM190835A 7/31/2021 AM190836A 7/31/2021 AM190837A 7/31/2021 AM190838A 7/31/2021 AM191004A 8/31/2021 AM191005A 8/31/2021 AM191006A 8/31/2021 AM191007A 8/31/2021 AM191008A 9/30/2021 AM191271A 10/31/2021 AM191272A 10/31/2021 AM191273A 10/31/2021 AM191274A 10/31/2021 AM191338A 11/30/2021 AM191339A 11/30/2021 AM191340A 11/30/2021 AM191341 12/31/2021 AM191342 12/31/2021 AM200109 12/31/2021 AM200110 12/31/2021 AM200111 12/31/2021

Other recalls by Amneal Pharmaceuticals of New York, LLC

  • D-0477-2024 Class II — Methylergonovine Maleate Tablets, USP, 0.2mg, 12-count bottle, Rx Only, Distribu (March 25, 2024)
  • D-0442-2024 Class I — Vancomycin Hydrochloride for Oral Solution, USP, 250 mg per 5 mL, packaged as (a (March 21, 2024)
  • D-0327-2024 Class II — Oseltamivir Phosphate for Oral Suspension 6mg/ml, 60 mL (reconstituted) bottle, (February 13, 2024)
  • D-0319-2024 Class II — Phenoxybenzamine Hydrochloride Capsules, USP 10mg, 100-count bottle, Rx only, Ma (January 15, 2024)
  • D-0426-2024 Class II — Divalproex Sodium Extended-release Tablets, USP 250 mg, Rx Only, 100 tablets, Ma (December 26, 2023)
  • D-0090-2024 Class II — Extended Phenytoin Sodium Capsules, USP, 100 mg, 100-count bottle, Distributed b (October 27, 2023)
  • D-0876-2023 Class II — Extended Phenytoin Sodium Capsules, USP, 100 mg, Rx Only, 100 capsules per bottl (May 30, 2023)
  • D-0756-2023 Class III — Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscula (May 8, 2023)
  • D-1362-2022 Class II — Divalproex Sodium Extended Release Tablets, USP, 250 mg, packaged in 100-count b (July 27, 2022)
  • D-0233-2022 Class II — Flocinolone Acetonide 0.01% Topical Oil, Body Oil, Rx, packaged in 4 oz. bottle, (November 4, 2021)